This is an oral medication in capsule form.
is a capsule taken twice daily by mouth. It is similar to another disease modifying therapy, Tecfidera
, but has a distinct chemical structure that has been shown to be better tolerated, with fewer reported gastrointestinal side effects than Tecfidera. Once in the body, Vumerity rapidly converts to the same active ingredient as Tecfidera. Although its exact mechanism of action is not known, Vumerity is thought to modulate the immune response to be less inflammatory and may have antioxidant properties that could be protective against damage to the brain and spinal cord.
Vumerity is approved by the FDA for the treatment of relapsing forms of multiple sclerosis to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease in adults.
to read the Society’s news bulletin on the FDA approval of Vumerity.
to read the Vumerity Prescribing Information for healthcare professionals.
to read the Vumerity Patient Information
Patient Support Program: Above MS
Financial Assistance ProgramAbove MS